Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021010937 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF SICKLE CELL DISEASES AND THALASSEMIA

Publication Number WO/2021/010937
Publication Date 21.01.2021
International Application No. PCT/US2019/000033
International Filing Date 17.07.2019
IPC
A61K 31/365 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
A61K 31/551 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • EMMAUS MEDICAL, INC. [US]/[US]
Inventors
  • NIIHARA, Yutaka
Agents
  • MCKINNEY, Jeffrey, A.
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SICKLE CELL DISEASES AND THALASSEMIA
(FR) PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE ET DE LA THALASSÉMIE
Abstract
(EN)
The present invention is generally directed to methods and compositions for the treatment of sickle cell diseases and thalassemia. It is more particularly directed to compositions containing L-glutamine, an L-glutamine salt or an L-glutamine derivative and at least one other active ingredient and methods using such compositions. In one aspect, the present invention is directed to a composition for treating sickle cell disease or β-thalassemia. The composition comprises: at least one gram of L-glutamine, an L-glutamine salt or an L-glutamine derivative; and, at least one gram of one type of fiber.
(FR)
La présente invention concerne de manière générale des procédés et des compositions pour le traitement de la drépanocytose et de la thalassémie. Elle concerne plus particulièrement des compositions contenant de la L-glutamine, un sel de L-glutamine ou un dérivé de L-glutamine et au moins un autre principe actif et des procédés utilisant de telles compositions. Dans un aspect, la présente invention concerne une composition pour le traitement de la drépanocytose ou de la ß-thalassémie. La composition comprend : au moins un gramme de L-glutamine, d'un sel de L-glutamine ou d'un dérivé de L-glutamine ; et au moins un gramme d'un type de fibre.
Also published as
EP2019742516
EP19742516.8
Latest bibliographic data on file with the International Bureau